These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 39029925)

  • 21. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
    Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
    Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
    Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
    Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells.
    Mishra HK; Pore N; Michelotti EF; Walcheck B
    Cancer Immunol Immunother; 2018 Sep; 67(9):1407-1416. PubMed ID: 29978334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers.
    Tang L; Sun Q; Li M; Yu X; Meng J; Zhang Y; Ma Y; Zeng A; Li Z; Liu Y; Xu X; Guo W
    Front Immunol; 2024; 15():1400177. PubMed ID: 38953027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.
    Boissel L; Betancur-Boissel M; Lu W; Krause DS; Van Etten RA; Wels WS; Klingemann H
    Oncoimmunology; 2013 Oct; 2(10):e26527. PubMed ID: 24404423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
    Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
    Front Immunol; 2022; 13():841859. PubMed ID: 35281028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B; Tumanut C; Li L; Corper A; Challa D; Chang A; Begum H; Farokhi E; Woods C; Fan X
    MAbs; 2024; 16(1):2381261. PubMed ID: 39048914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies.
    Luanpitpong S; Poohadsuan J; Klaihmon P; Issaragrisil S
    J Immunol Res; 2021; 2021():5562630. PubMed ID: 34337077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin.
    Zheng L; Wang H; Zhou J; Shi G; Ma J; Jiang Y; Dong Z; Li J; He YQ; Wu D; Sun J; Xu C; Li Z; Wang J
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38964787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
    Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
    Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
    Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
    J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.
    Liu E; Ang SOT; Kerbauy L; Basar R; Kaur I; Kaplan M; Li L; Tong Y; Daher M; Ensley EL; Uprety N; Nunez Cortes AK; Yang RZ; Li Y; Shaim H; Reyes Silva F; Lin P; Mohanty V; Acharya S; Shanley M; Muniz-Feliciano L; Banerjee PP; Chen K; Champlin RE; Shpall EJ; Rezvani K
    Front Immunol; 2021; 12():626098. PubMed ID: 33717142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
    Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S
    J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.